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ABSTRACT
Objective: To evaluate the hypoallergenicity of an
extensively hydrolysed (EH) casein formula
supplemented with Lactobacillus rhamnosus GG
(LGG).
Design: A prospective, randomised, double-blind,
placebo-controlled crossover trial.
Setting: Two study sites in Italy and The Netherlands.
Study participants: Children with documented cow’s
milk allergy were eligible for inclusion in this trial.
Interventions: After a 7-day period of strict avoidance
of cow’s milk protein and other suspected food
allergens, participants were tested with an EH casein
formula with demonstrated hypoallergenicity (control,
EHF) and a formula of the same composition with LGG
added at 10
8 colony-forming units per gram powder
(EHF-LGG) in randomised order in a double-blind
placebo-controlled food challenge (DBPCFC). After
absence of adverse reactions in the DBPCFC, an open
challenge was performed with EHF-LGG, followed by
a 7-day home feeding period with the same formula.
Main outcome measure: Clinical assessment of any
adverse reactions to ingestion of study formulae
during the DBPCFC.
Results: For all participants with conﬁrmed cow’s milk
allergy (n¼31), the DBPCFC and open challenge were
classiﬁed as negative.
Conclusion: The EH casein formula supplemented
with LGG is hypoallergenic and can be recommended
for infants and children allergic to cow’s milk who
require an alternative to formulae containing intact
cow’s milk protein.
Trial registration number: http://ClinicalTrials.gov
Identiﬁer: NCT01181297.
INTRODUCTION
Breast milk is the gold standard for infant
nutrition and is recommended for most
infants.
1 2 A cow’s milk-based infant formula
is most commonly used if a breast milk
substitute is needed during the ﬁrst year of
life.
1 However, allergy to cow’s milk protein
affects 2.2e2.8% of all infants.
34Diagnostic
conﬁrmation of cow’s milk allergy (CMA) is
based on clinical history, physical exam
and controlled elimination of cow’s milk
protein followed by challenge procedures,
including double-blind placebo-controlled
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ARTICLE SUMMARY
Article focus
- Hypoallergenic extensively hydrolysed (EH)
cow’s milk-based or amino acid-based formulae
are recommended for management of cow’s milk
allergy in formula-fed infants.
- Although Lactobacillus rhamnosus GG (LGG) has
over 25 years of safe use as a dietary probiotic,
the safety and hypoallergenic status of EH casein
formula supplemented with LGG has not yet been
demonstrated.
Key messages
- Supplementing the EH casein formula with LGG
to provide additional beneﬁts does not change its
hypoallergenic status.
- The LGG-supplemented EH formula can be safely
used for management of cow’s milk allergy in
infants and children.
Strengths and limitations of this study
- Testing the LGG-supplemented EH formula in
a properly designed double-blind placebo-
controlled food challenge in accordance with
accepted European Society of Pediatric Gastro-
enterology and Nutrition (ESPGHAN) and Amer-
ican Academy of Pediatrics standards to
establish hypoallergenicity is a major strength
of this study.
- One limitation is the potentially low novelty of our
ﬁnding. Because LGG is the most used dietary
probiotic, accumulated safety data for LGG as
a stand-alone dietary supplement in infants and
adults are available.
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Open Access Researchfood challenge (DBPCFC).
5 Quantiﬁcation of speciﬁc
IgE to cow’s milk is used to diagnose IgE-mediated CMA
and may eliminate the need to perform a DBPCFC for
conﬁrmation.
56A child may be considered allergic to
cow’s milk with no need for DBPCFC conﬁrmation if the
speciﬁc IgE concentration by CAP RAST is greater than
or equal to the 95% positive predictive value as estab-
lished in earlier studies (5 and 15 kUA/l for children
#1 year of age and >1 year of age, respectively).
67
Management of CMA is based on complete avoidance of
intact cow’s milk protein. One alternative, soy-based
formula, is generally not recommended, particularly for
infants younger than 6 months of age with non-IgE-
mediated manifestations of CMA, who are more likely to
develop concomitant soy allergy.
89Thus, formulae with
reduced allergenicity, such as those with extensively
hydrolysed (EH) protein, are recommended for
formula-fed infants with CMA.
281 0EH casein formula
has a long history of demonstrated efﬁcacy and safety to
manage infants and children with CMA.
11e13
Determination of b-lactoglobulin (bLG) level, a major
cow’s milk allergen, is a ﬁrst assessment of the suitability of
a substitute infant formula for infants and children with
CMA.
14 The minute amount of bLG detected in EH casein
formula
14 is in the lower range of the amounts detected in
breast milk (0.9e150 mg/l).
15 According to the European
Society of Pediatric Gastroenterology and Nutrition
(ESPGHAN) and the American Academy of Pediatrics,
a formula must be tested in a properly designed DBPCFC
and can be considered hypoallergenic when demon-
strated with 95% conﬁdence that at least 90% of infants
a n dc h i l d r e nw i t hc o n ﬁ r m e dC M Aw o u l dh a v en or e a c t i o n
to the formula under double-blind, placebo-controlled
conditions.
10 14 16 To control for possible false negatives,
a negative DBPCFC should be followed by an open chal-
lenge (OC) with the tested formula.
5 After negative chal-
lenges, further assessment of tolerance to the tested
formula during a 7-day feeding period to detect potential
late-onset reactions is also recommended.
10 14
Probiotics are live microorganisms which, when
administered in adequate amounts, confer a health
beneﬁt to the host.
17 Lactobacillus rhamnosus GG (LGG)
is the most studied probiotic, with demonstrated beneﬁts
when added to an EH formula, including decreased
severity of atopic dermatitis (AD),
18 19 reduced intestinal
inﬂammation
18 20 and faster induction of tolerance
21 in
infants with CMA and improved recovery from allergic
colitis.
20 We previously demonstrated that LGG was well
tolerated, promoted normal growth and transiently
colonised the intestine when added to an EH casein
formula fed to healthy term infants.
22 23 An EH formula
with the same casein hydrolysate and many years of
clinical experience of safety use in children with CMA
was demonstrated to be hypoallergenic in those children
in a DBPCFC trial.
13 However, the hypoallergenic status
of the EH casein formula with added LGG has not yet
been demonstrated. In the current study, we evaluated if
LGG addition to this EH casein formula affected its
hypoallergenic status for use in management of
conﬁrmed CMA in infants and children.
METHODS
Study design and participants
A randomised, double-blind, placebo-controlled prospec-
tive crossover trial was conducted at two study sites to
assess the hypoallergenicity of an EH casein formula with
the same formulation of a previously existing formula
(Nutramigen; Mead Johnson & Company, Evansville,
Indiana, USA; control, EHF) that differed only in
supplementation with LGG at 10
8 colony-forming units
per gram of powder (EHF-LGG). Each powdered formula
provided 2.8 g protein/100 kcal. The LGG raw material
used in the formula demonstrated absence of bLG, as
determined by an ELISA test with a detection limit of
0.1 mg/g (data on ﬁle).
Infants and children #14 years of age with conﬁrmed
CMA were eligible for this study if their allergic mani-
festations were under sufﬁcient control, so that a positive
response to a food challenge would be recognisable. In
addition, participants should have successfully
consumed the control formula within 1 week of study
enrolment. Exclusion criteria were presence of systemic
disease or illness that could compromise participation in
the study, use of b-blockers within 12 h of DBPCFC, use
of short-acting, medium-acting or long-acting antihista-
mines more than once within 3, 7 or 21 days of DBPCFC,
respectively, or oral steroids within 21 days of DBPCFC.
Adverse events were recorded throughout the study.
Conﬁrmation of CMA
Conﬁrmation of CMA required one of the following
criteria: (1) a positive DBPCFC to cow’s milk or cow’s
milk-based formula within 6 months of study enrolment;
(2) a positive conﬁrmatory value of CAP RAST (Phar-
macia, Uppsala, Sweden) to cow’s milk within 6 months
of study enrolment ($5k U A/l in participants #1 year of
age or $15 kUA/l in participants >1 year of age); (3) a
documented signiﬁcant adverse reaction to inadvertent
ingestion of cow’s milk or cow’s milk-based formula
within 6 months of enrolment plus a positive DBPCFC or
a conﬁrmatory CAP RAST value to cow’s milk within
12 months of enrolment or (4) a physician-documented
anaphylaxis to cow’s milk or cow’s milk-based formula
within 6 months of study enrolment plus a conﬁrmatory
CAP RAST value to cow’s milk within 12 months of
enrolment.
DBPCFC and OC
The hypoallergenicity of the EHF-LGG formula was
evaluated in a DBPCFC and OC, as described previ-
ously.
24 A 7-day period of strict elimination of cow’s milk
protein and other suspected food allergens preceded the
DBPCFC (ﬁgure 1). On study day 1 prior to the begin-
ning of the DBPCFC and OC, participants underwent
a physical examination and medical history and status of
allergic diseases was recorded. Participants were either
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lised for a minimum of 7 days prior to the DBPCFC. The
study sponsor had issued a list of 6-digit participant
numbers to each study site and the study coordinator
sequentially assigned a participant number to each
participant. The sponsor also created a separate
computer-generated randomisation list of participant
numbers that indicated the order in which each study
formula should be offered in the DBPCFC challenge. At
both study sites, the participant number was provided to
a third-party pharmacist who referenced the number
against the randomisation list in order to prepare
the EHF and EHF-LGG formulae in the assigned
randomised order for each participant.
In the DBPCFC, the EHF and EHF-LGG formulae fed in
randomised order were administered in an initial 5e10 ml
aliquot followed by gradually increasing volumes over
a maximum period of 120 min to provide a cumulative
volume of 150 ml. A minimum interval of approximately
120 min between the end of the challenge with the ﬁrst
formula separated the beginning of the challenge with the
second formula. Times of consumption and amounts of
study formula consumed during each challenge were
recorded. Any signs or symptoms present before (base-
line), during, or after the DBPCFC and OC were recorded
using a scoring system to rate severity. The skin was
observed for rash, urticaria/angioedema, or pruritus, with
the percentage of body area affected recorded. The upper
respiratory system was assessed for sneezing/itching, nasal
congestion, rhinorrhoea, or laryngeal symptoms, and the
lower respiratory system was assessed for wheezing. The
gastrointestinal system was evaluated for subjective symp-
toms such as nausea and abdominal pain and objective
symptoms such as vomiting and diarrhoea. Any changes in
signs or symptoms from baseline would have resulted in
classifying the challenge as positive and discontinuing the
participant from the study. If the DBPCFC was negative, an
OC with 150e250 ml of the EHF-LGG followed.
Home feeding period
To assess long-term tolerance and reveal any false-negative
results to the challenges, all participants with negative
Figure 1 Flow of participants
through the double-blind placebo-
controlled food challenge
(DBPCFC), open challenge (OC)
and home feeding period (EHF,
control formula; EHF-LGG,
intervention; CM, cow’s milk;
CMP, cow’s milk protein; CMA,
cow’s milk allergy).
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a minimum of 240 ml of EHF-LGG formula/day during
a 7-day home feeding period. Participants’ parents reco-
rded in a daily diary volume of formula consumed: pres-
ence and severity of vomiting, diarrhoea, rash, runny nose,
wheezing or any other symptoms (rated as mild, moderate
or excessive); number of bowel movements and overall
formula acceptance and tolerance (rated as satisfactory or
unsatisfactory). The investigator completed a ﬁnal evalu-
ation at the end of the 7-day home feeding period.
Table 1 Participants with conﬁrmed CMA: primary criterion used to conﬁrm CMA, age at CAP RAST to CM and CAP RAST
values and symptoms evoked by the participants’ most recent exposure to CMP
Primary criterion to
conﬁrm CMA Age (years)
CAP RAST
to CM (kUA/l)
Symptoms evoked after most recent
inadvertent CMP intake or DBPCFC to CMP
Positive DBPCFC to CMP within
6 months of study enrolment
0.7 70 Pruritus, rash, urticaria/angioedema, rhinorrhoea
0.9 12.2 Pruritus, rash, urticaria/angioedema
1.1 <0.35 Pruritus, rash
1.3 >100 Pruritus, rash, urticaria/angioedema
1.4 9.9 Pruritus, rash, urticaria/angioedema
1.6 15.7 Urticaria/angioedema, sneezing/itching,
laryngeal oedema
11.6 12.3 Laryngeal oedema
Conﬁrmatory CAP RAST to CM
within 6 months of study enrolment
0.6 7.16 Pruritus, rash, urticaria/angioedema, wheezing
0.8 17.1 Pruritus, rash, urticaria/angioedema
1.5 22.4 Pruritus, rash, urticaria/angioedema,
sneezing/itching
1.6 34.5 Pruritus, rash, vomiting
2.3 >100 *
2.4 61.8 Pruritus, rash, urticaria/angioedema, vomiting
Adverse reaction to inadvertent
CMP intake within 6 months and
positive CAP RAST to CM within
12 months of study enrolment
0.3 68.3 Pruritus, rash, urticaria/angioedema,
nasal congestion, sneezing/itching
0.4 6.09 Pruritus, rash, urticaria/angioedema, vomiting
0.5 4.59y Pruritus, rash, urticaria/angioedema,
nasal congestion, sneezing/itching
0.6 10.5 Pruritus, rash, urticaria/angioedema, vomiting
0.6 9.01 Pruritus, urticaria/angioedema, nasal
congestion, sneezing/itching
0.6 57.3 Pruritus, rash, urticaria/angioedema,
nasal congestion, sneezing/itching,
laryngeal oedema
0.7 7.46 Pruritus, rash, urticaria/angioedema,
nasal congestion, rhinorrhoea, sneezing/itching
0.7 9.05 Pruritus, rash, urticaria/angioedema,
rhinorrhoea, sneezing/itching
0.8 6.84 Pruritus, rash, wheezing, vomiting
1.0 29.1 Pruritus, rash, urticaria/angioedema
1.0 29.5 Pruritus, rash, urticaria/angioedema
1.1 60.8 Pruritus, rash, urticaria/angioedema, vomiting
1.3 >100 Urticaria/angioedema, rhinorrhoea,
wheezing, diarrhoea, vomiting
1.4 23.9 Pruritus, rash, urticaria/angioedema, vomiting
1.5 25.0 Pruritus, rash, urticaria/angioedema, vomiting
1.6 30.5 Pruritus, rash, urticaria/angioedema,
rhinorrhoea, sneezing/itching
Anaphylaxis to CMP within 6 months
and positive CAP RAST to CM within
12 months of study enrolment
0.3 8.01 Pruritus, rash, urticaria/angioedema,
systemic anaphylaxis
0.4 5 Pruritus, rash, urticaria/angioedema,
nasal congestion, rhinorrhoea,
sneezing/itching, systemic anaphylaxis
*Participant had a history suggestive of CMA beginning at 6 months of age and ongoing symptoms of atopic dermatitis at enrolment.
yParticipant had sufﬁcient evidence of CMA (exhibited multiple symptoms upon inadvertent CM intake within 3 months of enrolment) although
CAP RAST to CM was slightly <5k U A/l.
CM, cow’s milk; CMA, cow’s milk allergy; CMP, cow’s milk protein; DBPCFC, double-blind placebo-controlled food challenge.
4 Muraro A, Hoekstra MO, Meijer Y, et al. BMJ Open 2012;2:e000637. doi:10.1136/bmjopen-2011-000637
LGG-supplemented extensively hydrolysed formula maintains hypoallergenic statusSample size determination
In a study with a binomial outcome (reaction versus no
reaction), the sample size can be determined by calcu-
lating a binomial CI for p, the probability of having
a reaction, as demonstrated previously.
13 In the case of
0 observed reactions, the upper 95% CI for p is <0.10
when the sample size is 29 participants. Thus studying at
least 29 participants and having none classiﬁed as posi-
tive in the DBPBFC allows the conclusion that the study
provided 95% conﬁdence that at least 90% of children
with conﬁrmed CMA who ingest the tested formula
would have no reaction.
10 16 Data were prepared using
SAS
 V.8.
Ethics approval
The research protocol and informed consent were
approved by the Medical Ethics Committees of the The
Food Allergy Referral Centre, Department of Pediatrics,
Veneto Region, Universita ` degli Studi di Padova, Padova,
Italy and the Wilhelmina Children’s Hospital, University
Medical Centre, Utrecht, The Netherlands. The study
complied with good clinical practice guidelines and the
1996 version of the Declaration of Helsinki.
RESULTS
Of the 34 children enrolled in the study between April
2003 and February 2004, a total of 33 (males, 19;
females, 14) completed the DBPCFC, OC and 7-day
home feeding period (one participant who was enrolled
but did not meet inclusion criteria was discontinued
from the study) (ﬁgure 1). Two participants were
excluded from further analyses because CAP RAST to
cow’s milk was lower than the conﬁrmatory value for
CMA. Neither participant experienced allergic reactions
to the study formulae. Of the remaining 31 participants,
13 were <1 year, 17 were 1e3 years and 1 was 11 years of
age. The primary criterion used to conﬁrm ongoing
CMA, values for CAP RAST to cow’s milk and symptoms
evoked after the most recent inadvertent cow’s milk
protein intake or DBPCFC are summarised in table 1 for
these participants.
Ongoing allergic diseases including AD, asthma and/
or allergic rhinitis were noted in 29 participants at study
entry. Two participants reported a history of AD but no
active allergic manifestation at study entry. Participants’
status of allergic manifestations and presence of food
allergies other than CMA at enrolment are shown in
ﬁgure 2A,B, respectively. Ongoing allergy to multiple
foods was reported for 29 participants, with 18 partici-
pants having two or more reported food allergies in
addition to CMA.
After the pre-challenge 7-day period of cow’s milk
protein elimination, 29 of 31 participants had no allergic
symptoms and remained asymptomatic throughout the
DBPCFC and OC. Of the two remaining participants,
one had no change in the mild rhinorrhoea reported at
baseline and one had an improvement in the pruritus
and rash reported at baseline. The DBPCFC and OC
were thus classiﬁed as negative for all participants.
Parent-recorded diaries during the home feeding period
were returned for 30 participants and indicated that
overall acceptance and tolerance of the EHF-LGG
formula was generally good. Mean daily intake (mL/
day6SD) reported was 5466251 and 5226132 for
participants <1 year and 1e3 years of age, respectively,
and 561 for the 11-year-old participant. Mean daily stool
frequencies (6SD) were 1.960.5 and 1.760.9 for
participants <1 year and 1e3 years of age, respectively,
and 1.3 for the 11-year-old. No serious adverse events
were reported during the DBPCFC, OC or home feeding
period.
DISCUSSION
These ﬁndings demonstrate that a hypoallergenic EH
casein hydrolysate formula remains hypoallergenic
following the addition of LGG, satisfying both
Figure 2 Medical history of participants with conﬁrmed cow’s
milk allergy (n¼31): (A) ongoing and resolved clinical allergic
manifestations at enrolment and (B) number of participants
who reported allergy to foods other than cow’s milk at
enrolment.
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lines. In this study, all 31 study participants with
conﬁrmed CMA had a previous history of experiencing
one or more types of allergic symptoms in the skin,
respiratory and/or gastrointestinal systems or had
systemic anaphylaxis after ingestion of cow’s milk
protein, meeting recognised criterion to conﬁrm CMA
using a combination of convincing symptoms upon
exposure to cow’s milk protein and a strongly positive
conﬁrmatory value of speciﬁc IgE to cow’s milk by
RAST.
6 72 4In accordance with reports of sensitisation to
other food allergens commonly observed in children
with CMA,
13 24 allergy to one or more foods in addition
to cow’s milk was reported in 94% of participants in this
study. After 7 days of strict cow’s milk protein elimina-
tion from the diet, 29 of 31 participants had no allergic
symptoms and remained asymptomatic throughout the
DBPCFC and OC, whereas the other two had mild
symptoms that either did not change or improved
during the challenges. No serious adverse events were
reported during the DBPCFC, OC or the 7-day home
feeding period.
The addition of probiotics in formula used for
management of CMA requires that they be proven safe
and are well tolerated. LGG has over 25 years of safe
use
25 including administration to preterm infants
26 or to
infants perinatally who were at high risk of allergy, in
whom normal growth was demonstrated up to 2e4 years
of age.
27 28 To justify use, addition of a probiotic must
also be shown to be of beneﬁt. Early gut microbial
colonisation is associated with modulation of inﬂamma-
tion and expression of allergy.
18 20 29 30 LGG adminis-
tration to atopic pregnant women followed by postnatal
administration to their infants was associated with lower
incidence of AD at 2, 4 and 7 years of age compared with
placebo.
30 Additionally, anti-inﬂammatory effects of
LGG accompanied by amelioration of symptoms were
observed in infants experiencing AD as a manifestation
of CMA.
19 31 In a study using fecal calprotectin as
a marker of intestinal inﬂammation, infants with
presumptive allergic colitis were randomised to receive
an EH formula with or without LGG and the same casein
hydrolysate as the formulae in the current study.
20 After
a 4-week feeding period, blood in stools, characteristic of
allergic colitis, disappeared in all infants in the LGG-
supplemented group versus only 63% in the non-
supplemented group. The LGG-supplemented group
also experienced a larger decrease in fecal calprotectin
level. In a recent study, EH casein formula with LGG was
demonstrated to accelerate the time of acquisition of
tolerance to cow’s milk protein in infants with CMA after
6 and 12 months of feeding.
21
We previously demonstrated that LGG added to an EH
casein formula was well tolerated and transiently colon-
ised the intestinal tract of healthy term infants.
22 Growth
and other nutrition parameters, including circulating
fatty acid levels, were demonstrated to be normal in
healthy term infants who received this formula up to
4 months of age.
23 Available data suggest that the LGG-
supplemented EH casein formula assessed in the current
study provides additional beneﬁts of better management
of allergic colitis, as well as faster tolerance acquisition,
in infants with CMA that are not observed with the
non-supplemented formula. We tested the EH casein
formula supplemented with LGG according to estab-
lished criteria and demonstrated that its hypoallergenic
status is maintained. Therefore, this formula can be
recommended for infants and children with CMA who
require an alternative to formulae containing intact
cow’s milk protein.
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